Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Vanta™ SCS gives you an advantage over pain. This revolutionary recharge-free device offers optimized longevity, DTM™ SCS endurance programming, and unmatched MRI access.Download Brochure
Learn about Vanta™ SCS.
High-performance recharge-free neurostimulator
Vanta™ SCS is a high-performance recharge-free device offering optimized longevity.
DTM™ SCS endurance therapy
DTM™ SCS endurance therapy is an energy modified differential target multiplexed therapy offering meaningful pain relief, satisfaction, and quality of life improvements.2
Clinical evidence for DTM™ SCS endurance therapy2:
Meaningful pain reduction
cm reduction in VAS for overall
pain from baseline to 12-months
Quality of life improvements
of patients improved in degree
of disability at 12-months
of patients were
satisfied with therapy at 12-months
The Medtronic adaptor extension connects with certain Boston Scientific™ or Nevro™ leads.§ This enables patients with existing leads to gain access to meaningful pain relief with DTM™ SCS endurance therapy offered with recharge-free convenience on Vanta™ INS.
|Width||1.1 cm (.44in)|
U.S. clinician services
Settings used from Proclaim™ clinician manual. Nominal settings 12 hours per day: 50-Hz frequency. 225-μs pulse width, and 5-mA amplitude at 500-ohms impedance. Energy modeling is the same for model 3660 and model 3670.
Settings from Boston Scientific's Alpha™ IFU. Programmed at 4.1mA, 280us. 40Hz. 1 area, 730 Ohms, 2 contacts.
Under specific conditions. Refer to product labeling for full list of conditions. Patients with non-Medtronic leads and an EMBSNV20 adaptor extension are not eligible for an MRI.
Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Provenzano, Amirdelfan, Grewal, et al. Modeling energy demands of a reduced-energy derivative of DTM™ stimulation on rechargeable and recharge-free SCS systems. Poster presented at: American Society of Regional Anesthesia and Pain Medicine (ASRA) Annual Pain Medicine Meeting; Nov. 17–19, 2022; Orlando, FL, USA.
Provenzano, Peacock, Fishman, et al. A prospective multi-center study of a reduced-energy DTM™ stimulation derivative: Long-term outcomes in therapy naïve patients. Poster presented at: American Society of Regional Anesthesia and Pain Medicine (ASRA) Annual Pain Medicine Meeting; Nov. 17–19, 2022; Orlando, FL, USA.
Desai MJ, Hargens LM, Breitenfeldt MD, et al. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine. 2015;40(9):E531–537